MorphoSys Signs Long-Term Alliance with Pfizer on Sloning Technology Platform
Advertisement
MorphoSys AG announced the signing of a non-exclusive license and technology transfer agreement between its subsidiary Sloning BioTechnology GmbH and Pfizer. The agreement covers the installation, training and use of Sloning's technology platform Slonomics® for fabrication of highly-diverse gene and protein libraries at Pfizer's subsidiary Rinat Neuroscience Corp. in South San Francisco. The MorphoSys subsidiary will receive an upfront payment in 2010, and stands to receive annual license fees over the patent lifetime of the Slonomics technology platform. Further financial details of the agreement were not disclosed.
"This significant alliance around the Slonomics technology, only weeks after we closed the acquisition of Sloning, clearly illustrates the potential value of the platform," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "This alliance with Pfizer creates immediate value for our shareholders and is just the beginning of what we expect to be a considerable return-on-investment from the combined technology platforms of MorphoSys and Sloning in the years ahead."
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Avantor to Acquire Ritter GmbH and its Affiliates
Iktos Announces Collaboration With Pfizer in AI for Drug Design - “We are proud to work with Pfizer and to have their scientists use our software in their early discovery programs”
ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials for Anticoagulant TB-402
New technique illuminates DNA helix - “We figured out a very clever trick to measure the torsional stiffness of DNA”
Measles infections erase immunological memory
Researchers eyeing new way to measure elusive zinc
Hospital germs have their flaws too - Researchers discovered a target for novel medications
Moderate coffee drinking 'more likely to benefit health than to harm it' say experts
AiCuris successfully completed phase I for novel herpes compound
